Heinz Wiendl

Q: What Schools Are Affiliated With Heinz Wiendl

Heinz Wiendl is affiliated with the following schools: University of Erlangen–Nuremberg, University of Sydney, University of Tübingen, University of Würzburg, University of Münster

Heinz Wiendl's AcademicInfluence.com Rankings

Heinz Wiendl

Medical

#1036

World Rank

#1330

Historical Rank

Neurology

#103

World Rank

#158

Historical Rank

medical Degrees

Heinz Wiendl

Philosophy

#5095

World Rank

#7819

Historical Rank

Logic

#2428

World Rank

#3418

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Heinz Wiendl's Degrees

Doctorate Medicine University of Münster
PhD Neurology University of Münster

Why Is Heinz Wiendl Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Heinz Wiendl is a German neurologist and professor at the University Hospital Muenster. He is known for his works in the field of nervous system inflammation and multiple sclerosis. Biography Wiendl studied psychology and medicine from 1989 to 1996 at the University of Erlangen-Nuremberg, Germany, Duke University, North Carolina, and Bale University, Switzerland. He obtained his MD in 1996. In the following years, he was a scholar of the German Research Council at the Max Planck Institute of Neurobiology , worked as a clinical and research fellow at the Department of Neurology Tuebingen, received board certification and completed his habilitation . In 2005 he was appointed as a professor of neurology and head of the clinical research group for MS and neuroimmunology in Wuerzburg and acted as a vice-chair of the Department of Neurology. In 2010 he was recruited to the University of Muenster, where he accepted the position as a director of the Department of Neurology – Inflammatory Diseases of the Nervous System and Neurooncology. Since 1 May 2013 he is director of the Department of Neurology in Muenster.

(See a Problem?)

Heinz Wiendl's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. (2003) (396)
Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis (2002) (351)
A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 (2002) (341)
Acute disseminated encephalomyelitis: an update. (2005) (340)
Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. (2010) (323)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis (2018) (319)
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. (2000) (311)
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro (2006) (306)
Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. (2013) (292)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis (2004) (278)
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis (2014) (256)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis (2014) (240)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (2015) (237)
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis (2018) (224)
Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) (220)
A PD‐1 polymorphism is associated with disease progression in multiple sclerosis (2005) (220)
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations (2008) (218)
The role of regulatory T cells in multiple sclerosis (2008) (211)
Immunobiology of muscle: advances in understanding an immunological microenvironment. (2005) (192)
Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. (2012) (191)
Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients (2007) (190)
Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis (2018) (190)
HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. (2007) (189)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) (2011) (189)
The humoral response in the pathogenesis of gluten ataxia (2002) (187)
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results (2014) (160)
Diagnostic criteria for Susac syndrome (2016) (158)
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond (2015) (158)
Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. (2005) (155)
GluR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis (2001) (153)
Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS (2005) (153)
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society (2016) (153)
Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice (2014) (146)
l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients (2013) (144)
CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. (2009) (131)
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation (2016) (127)
Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS (2013) (127)
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. (2002) (123)
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells (2014) (123)
Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. (2003) (120)
CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. (2016) (120)
Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease (2015) (120)
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort (2012) (120)
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic (2020) (119)
Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells (2007) (118)
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis (2015) (117)
DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis (2018) (116)
Human muscle cells express a B7‐related molecule, B7‐H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies (2003) (115)
Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. (2016) (115)
Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series (2014) (114)
Immune Cells Contribute to Myelin Degeneration and Axonopathic Changes in Mice Overexpressing Proteolipid Protein in Oligodendrocytes (2006) (111)
Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA‐G (2000) (109)
Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity (2014) (106)
Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy (2011) (105)
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation (2016) (104)
Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration. (2017) (102)
CNS inflammation and neuronal degeneration is aggravated by impaired CD200–CD200R-mediated macrophage silencing (2008) (100)
Stromal Interaction Molecules 1 and 2 Are Key Regulators of Autoreactive T Cell Activation in Murine Autoimmune Central Nervous System Inflammation (2009) (100)
TWIK-related Acid-sensitive K+ Channel 1 (TASK1) and TASK3 Critically Influence T Lymphocyte Effector Functions* (2008) (100)
The impact of lesion location on dysphagia incidence, pattern and complications in acute stroke. Part 1: dysphagia incidence, severity and aspiration (2015) (98)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders—A Systematic Review (2018) (98)
Fatal PML associated with efalizumab therapy (2012) (98)
Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis1 (2008) (97)
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort (2013) (96)
The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. (2003) (95)
Optimizing therapy early in multiple sclerosis: An evidence-based view. (2015) (91)
Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells (2016) (91)
Expression of toll‐like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL‐8 release, and up‐regulation of NKG2D‐ligands (2006) (90)
TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. (2009) (90)
Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid (2020) (88)
Neurons as targets for T cells in the nervous system (2013) (88)
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children (2011) (86)
CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability (2009) (86)
Fingolimod treatment promotes regulatory phenotype and function of B cells (2015) (85)
Cathepsin G, and Not the Asparagine-Specific Endoprotease, Controls the Processing of Myelin Basic Protein in Lysosomes from Human B Lymphocytes1 (2004) (85)
NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody (2017) (84)
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice (2011) (84)
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study (2022) (83)
Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier (2016) (81)
Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects (2019) (81)
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis (2016) (81)
Cytotoxic CD8+ T Cell–Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death (2009) (80)
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G (2017) (79)
Multiple sclerosis therapeutics (2009) (79)
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment (2019) (78)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2019) (77)
The role of dendritic cells in CNS autoimmunity (2010) (77)
Immunoadsorption therapy in autoimmune encephalitides (2016) (76)
T cell suppression by naturally occurring HLA‐G‐expressing regulatory CD4+ T cells is IL‐10‐dependent and reversible (2009) (76)
Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. (2009) (76)
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis (2013) (76)
From the Background to the Spotlight: TASK Channels in Pathological Conditions (2010) (76)
B7‐H1 restricts neuroantigen‐specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis (2008) (75)
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy (2013) (75)
Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. (2011) (75)
Immune mechanisms of stroke. (2012) (75)
Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice (2014) (75)
A β-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis (2008) (75)
Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis (2005) (74)
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro (2005) (74)
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (2004) (73)
CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing (2016) (73)
Natalizumab-associated PML (2017) (73)
Computed tomography–based quantification of lesion water uptake identifies patients within 4.5 hours of stroke onset: A multicenter observational study (2016) (72)
Localization of UDP-GlcNAc 2-epimerase/ManAc kinase (GNE) in the Golgi complex and the nucleus of mammalian cells. (2005) (72)
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis (2016) (72)
Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges (2021) (71)
Intracerebral Dendritic Cells Critically Modulate Encephalitogenic versus Regulatory Immune Responses in the CNS (2009) (71)
Distinct cognitive impairments in different disease courses of multiple sclerosis—A systematic review and meta-analysis (2017) (71)
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) (2020) (71)
CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy (2012) (71)
Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity (2018) (69)
CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke (2014) (69)
Cytosolic RIG-I–like helicases act as negative regulators of sterile inflammation in the CNS (2011) (68)
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. (2012) (68)
Specific central nervous system recruitment of HLA‐G+ regulatory T cells in multiple sclerosis (2009) (68)
Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease (2018) (68)
Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. (2009) (68)
Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value (2004) (68)
Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis (2010) (68)
IL-17 Silencing Does Not Protect Nonobese Diabetic Mice from Autoimmune Diabetes (2012) (67)
PML risk stratification using anti-JCV antibody index and L-selectin (2016) (67)
Immune reconstitution therapies: concepts for durable remission in multiple sclerosis (2019) (66)
Cytoplasmic translocation of Olig2 in adult glial progenitors marks the generation of reactive astrocytes following autoimmune inflammation (2006) (66)
A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation (2003) (64)
Combined therapy of cerebral arteriovenous malformations: histological differences between a non-adhesive liquid embolic agent and n-butyl 2-cyanoacrylate (NBCA). (2002) (64)
The Contribution of TWIK-Related Acid-Sensitive K+-Containing Channels to the Function of Dorsal Lateral Geniculate Thalamocortical Relay Neurons (2006) (64)
The ups and downs of multiple sclerosis therapeutics (2001) (63)
Primary angiitis of the central nervous system: diagnosis and treatment (2018) (63)
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values (2016) (62)
Redefining the heterogeneity of peripheral nerve cells in health and autoimmunity (2020) (61)
Switching from natalizumab to fingolimod (2015) (61)
Blocking of &agr;4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice (2014) (60)
TRPM2 Cation Channels Modulate T Cell Effector Functions and Contribute to Autoimmune CNS Inflammation (2012) (60)
Comparative efficacy of switching to natalizumab in active multiple sclerosis (2015) (60)
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) (2020) (60)
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) (2020) (60)
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study (2017) (60)
Upregulation of K2P5.1 potassium channels in multiple sclerosis (2010) (59)
CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome (2019) (59)
Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis (2010) (59)
Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? (2007) (58)
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? (2007) (58)
Rasmussen encephalitis treated with natalizumab (2013) (57)
Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents (2019) (57)
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. (2010) (56)
The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice (2009) (55)
Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management (2017) (55)
Treatment and treatment trials in multiple sclerosis (2007) (55)
The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. (2006) (54)
Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies (2010) (54)
Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells (2008) (54)
Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens (2015) (54)
Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ. (2012) (52)
Immune circuitry in the peripheral nervous system (2006) (52)
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature (2020) (52)
Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. (2014) (52)
FOXP3+ T regulatory cells in idiopathic inflammatory myopathies (2010) (52)
Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis (2013) (51)
An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis (2010) (51)
Human CD4+HLA‐G+ regulatory T cells are potent suppressors of graft‐versus‐host disease in vivo (2014) (51)
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis. (2015) (51)
Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis (2020) (51)
Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G (2007) (51)
Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis (2016) (51)
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study (2020) (51)
Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany. (2015) (50)
Long-term effects of dalfampridine in patients with multiple sclerosis (2014) (49)
Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies (2003) (48)
Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology (2016) (48)
Treatment choices and neuropsychological symptoms of a large cohort of early MS (2018) (48)
The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. (2008) (47)
Pharmacological Treatment of Early Multiple Sclerosis (2008) (46)
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus (2011) (46)
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration (2019) (46)
The impact of lesion location on dysphagia incidence, pattern and complications in acute stroke. Part 2: Oropharyngeal residue, swallow and cough response, and pneumonia (2017) (45)
Modulation of T-effector function by imatinib at the level of cytokine secretion. (2007) (45)
Skeletal muscle cells actively shape (auto)immune responses. (2018) (45)
Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system (2012) (45)
Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. (2011) (44)
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) (2021) (44)
Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. (2003) (44)
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis (2020) (44)
Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis (2013) (43)
Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration (2016) (43)
Immunological and clinical consequences of treating a patient with natalizumab (2012) (43)
Rasmussen encephalitis with active inflammation and delayed seizures onset (2004) (42)
Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. (2010) (42)
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis (2017) (41)
Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells (2018) (41)
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus (2021) (41)
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies (2007) (41)
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19 (2021) (41)
Ineffective treatment of PML with pembrolizumab (2019) (40)
An Autoreactive γδ TCR Derived from a Polymyositis Lesion1 (2002) (40)
Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking (2014) (39)
Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. (2019) (39)
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course (2013) (39)
Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis (2014) (38)
Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease (2016) (38)
Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. (2007) (38)
Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration (2019) (38)
Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. (2009) (38)
Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid (2015) (38)
Death receptor-mediated apoptosis in human malignant glioma cells: Modulation by the CD40/CD40L system (2005) (37)
CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid β-related angiitis. (2012) (37)
The two-pore domain potassium channel TASK3 functionally impacts glioma cell death (2008) (37)
Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis (2008) (37)
Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke (2017) (37)
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID) (2015) (37)
Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyte‐directed CD8+ T cell attack (2009) (37)
Liver X receptor activation promotes differentiation of regulatory T cells (2017) (36)
„Chronische zerebrospinale venöse Insuffizienz“ und Multiple Sklerose (2010) (36)
CT versus MR Techniques in the Detection of Cervical Artery Dissection (2017) (36)
The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis (2012) (36)
Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation. (2001) (35)
DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning (2018) (34)
The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis. (2007) (34)
Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation (2010) (34)
Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo (2003) (34)
Dendritic cell vaccination in autoimmune disease (2013) (34)
Sex bias in MHC I-associated shaping of the adaptive immune system (2018) (33)
Immunomodulatory treatment strategies in multiple sclerosis (2008) (33)
Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3 (2018) (33)
Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis (2017) (33)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis (2015) (33)
Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies (2007) (33)
Evidence of a pathogenic role for CD8+ T cells in anti-GABAB receptor limbic encephalitis (2016) (33)
CADASIL: underdiagnosed in psychiatric patients? (2005) (33)
Cladribine — an old newcomer for pulsed immune reconstitution in MS (2017) (32)
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab (2019) (32)
Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. (2003) (32)
Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies (2003) (32)
[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]. (2000) (32)
DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis☆ (2013) (32)
Comparative efficacy of first-line natalizumab vs IFN-&bgr; or glatiramer acetate in relapsing MS (2016) (31)
Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis (2011) (31)
Oral Disease-Modifying Treatments for Multiple Sclerosis (2007) (31)
Prothrombin and factor X are elevated in multiple sclerosis patients (2016) (31)
Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation? (2017) (31)
Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets (2017) (31)
Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies? (2013) (30)
The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis (2020) (30)
Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. (2013) (30)
Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis (2012) (30)
Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles. (2015) (30)
Diffusion Abnormality in Balo’s Concentric Sclerosis: Clues for the Pathogenesis (2004) (30)
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis (2015) (30)
Novel pathomechanisms in inflammatory neuropathies (2017) (29)
Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. (2019) (29)
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity (2020) (29)
Expression of the B 7-Related Molecule B 7-H 1 by Glioma Cells : A Potential Mechanism of Immune Paralysis 1 (2003) (29)
Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2 (2021) (28)
Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration (2016) (28)
Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release (2018) (28)
Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders (2011) (28)
CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance. (2016) (28)
Muscle-derived positive and negative regulators of the immune response (2005) (28)
Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve (2010) (28)
Ocrelizumab initiation in patients with MS (2020) (27)
Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. (2013) (27)
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters (2018) (27)
Vitiligo after alemtuzumab treatment (2018) (27)
Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes (2003) (27)
A human post-mortem brain model for the standardization of multi-centre MRI studies (2015) (27)
The future of multiple sclerosis therapy. (2009) (27)
B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells (2010) (27)
Implications of dietary salt intake for multiple sclerosis pathogenesis (2016) (27)
Ion channels in autoimmune neurodegeneration (2011) (27)
Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. (2010) (27)
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications (2015) (26)
Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease (2019) (26)
The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis (2019) (26)
TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. (2020) (26)
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis (2015) (26)
Immune therapy of multiple sclerosis--future strategies. (2012) (26)
The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE (2009) (26)
HLA-G 2012 conference: the 15-year milestone update. (2013) (26)
Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS (2013) (25)
Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells (2015) (25)
Advances in pathogenic concepts and therapeutic agents in Rasmussen’s encephalitis (2002) (25)
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension (2020) (25)
Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS) (2018) (25)
The quality of cortical network function recovery depends on localization and degree of axonal demyelination (2017) (25)
CD4+NKG2D+ T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation (2013) (25)
Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus (2018) (25)
Acute and chronic structural effects of pilocarpine on monkey outflow tissues. (1998) (25)
Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients (2011) (25)
Immune signatures of prodromal multiple sclerosis in monozygotic twins (2020) (24)
B7-H1 shapes T-cell–mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity (2016) (24)
Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis (2018) (24)
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis (2013) (24)
Analysis of the C/T(-1) single nucleotide polymorphism in the CD40 gene in multiple sclerosis. (2006) (24)
Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study (2018) (24)
HLA-G in the nervous system. (2007) (23)
Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. (2008) (23)
Idiopathic inflammatory myopathies: Current and future therapeutic options (2008) (23)
Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study (2015) (23)
Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. (2020) (23)
Complement Activation Is a Prominent Feature of MOGAD (2021) (23)
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF (2019) (23)
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”) (2015) (23)
Intercellular exchanges of membrane fragments (trogocytosis) between human muscle cells and immune cells: A potential mechanism for the modulation of muscular immune responses (2009) (22)
Early and Degressive Putamen Atrophy in Multiple Sclerosis (2015) (22)
Defective synaptic transmission causes disease signs in a mouse model of juvenile neuronal ceroid lipofuscinosis (2017) (22)
Treatment of active secondary progressive multiple sclerosis with treosulfan (2007) (22)
α4-integrin receptor desaturation and disease activity return after natalizumab cessation (2017) (22)
Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11β-hydroxysteroid dehydrogenases in multiple sclerosis: Implications for lesion pathogenesis (2010) (22)
Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection (2014) (22)
Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium (2018) (22)
An assay to quantify species-specific anti-JC virus antibody levels in MS patients (2013) (21)
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab (2021) (21)
Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. (2012) (21)
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres (2021) (21)
CD4+ CD25+ FoxP3+ regulatory T cells suppress cytotoxicity of CD8+ effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level (2012) (21)
PD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation (2009) (21)
Does Device Selection Impact Recanalization Rate and Neurological Outcome? (2020) (21)
Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study (2018) (21)
The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion (2016) (21)
Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9) (2010) (21)
Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity (2018) (21)
[Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis]. (2008) (21)
Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center (2019) (20)
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy (2016) (20)
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis (2021) (20)
Con: Regulatory T cells are protective in ischemic stroke. (2013) (20)
Risks and benefits of multiple sclerosis therapies: need for continual assessment? (2011) (20)
Apraxia profile differentiates behavioural variant frontotemporal from Alzheimer's dementia in mild disease stages (2014) (20)
Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis (2014) (20)
Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis (2010) (20)
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation (2021) (20)
Stroke induces disease-specific myeloid cells in the brain parenchyma and pia (2022) (19)
Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease (2021) (19)
Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis (2021) (19)
Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies (2019) (19)
Apraxia profiles—A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease (2018) (19)
The NKG2D – IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies (2015) (18)
How patients with multiple sclerosis acquire disability (2022) (18)
Clonal expansions of pathogenic CD8+ effector cells in the CNS of myelin mutant mice (2007) (18)
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation (2018) (18)
The inflamed peripheral nervous system: update on immune therapies (2006) (18)
Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis. (1998) (18)
Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review (2019) (18)
Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis (2016) (18)
FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies (2014) (18)
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (2022) (18)
Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock? (2017) (17)
Shared neural correlates of limb apraxia in early stages of Alzheimer's dementia and behavioural variant frontotemporal dementia (2016) (17)
The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. (2016) (17)
Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter (2013) (17)
14‐3‐3 Proteins regulate K2P5.1 surface expression on T lymphocytes (2017) (17)
March 2003: a 41 -year-old female with a solitary lesion in the liver. (2003) (17)
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array (2015) (17)
ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential (2016) (17)
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. (2013) (16)
Anti-JC-virus antibody prevalence in a German MS cohort (2012) (16)
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. (2018) (16)
Antigen-Specific Blockade of Lethal CD8 T-Cell Mediated Autoimmunity in a Mouse Model of Multiple Sclerosis1 (2009) (16)
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies (2019) (16)
Evaluation of soluble HLA-G as a biomarker for multiple sclerosis (2011) (16)
Akute disseminierte Enzephalomyelitis (2005) (16)
Expert opinion on the use of cladribine tablets in clinical practice (2020) (16)
Blocking of α 4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice (2014) (16)
Therapeutic Approaches to Multiple Sclerosis (2010) (16)
Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis (2020) (15)
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis (2021) (15)
Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination (2018) (15)
The trials and errors in MS therapy. (2008) (15)
Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation (2018) (14)
Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency (2020) (14)
Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010–2015 (2016) (14)
Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination (2018) (14)
Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis. (2019) (14)
[Revision of McDonald's new diagnostic criteria for multiple sclerosis]. (2006) (14)
Monoclonal antibodies in neuroinflammatory diseases (2013) (14)
The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy (2009) (14)
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study (2021) (14)
Therapeutic Approaches to Multiple Sclerosis (2010) (14)
The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis (2003) (14)
Human myoblasts modulate the function of antigen-presenting cells (2008) (14)
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine (2010) (14)
Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study (2019) (14)
[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis]. (2005) (14)
Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS (2016) (13)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
Smad 7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis (2010) (13)
Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study (2021) (13)
Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis (2022) (13)
DGN-Leitlinie Diagnostik und Therapie der Multiplen Sklerose (2014) (13)
[Multiple sclerosis -- a channelopathy? Targeting ion channels and transporters in inflammatory neurodegeneration]. (2009) (13)
[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology]. (2011) (13)
Defining response profiles after alemtuzumab (2018) (13)
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020 (2020) (13)
Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System (2018) (13)
Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study (2020) (13)
Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A (2010) (13)
Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation (2008) (12)
Iatrogenic immunosuppression with biologics in MS (2009) (12)
The two‐pore domain K2P channel TASK2 drives human NK‐cell proliferation and cytolytic function (2015) (12)
Bcl6 controls meningeal Th17–B cell interaction in murine neuroinflammation (2021) (12)
Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS (2020) (12)
Amygdala enlargement and emotional responses in (autoimmune) temporal lobe epilepsy (2018) (12)
Immunophenotyping of cerebrospinal fluid cells by Chipcytometry (2018) (12)
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years (2022) (12)
Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose (2012) (12)
Intubation, tracheostomy, and decannulation in patients with Guillain–Barré–syndrome—does dysphagia matter? (2019) (12)
Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner (2014) (12)
Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? (2017) (12)
Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. (2020) (12)
Janus head: the dual role of HLA-G in CNS immunity (2011) (12)
Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation (2021) (12)
Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO) (2013) (12)
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies (2019) (12)
Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D? (2019) (12)
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity (2021) (11)
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients (2022) (11)
An In Vitro Model of the Blood-brain Barrier Using Impedance Spectroscopy: A Focus on T Cell-endothelial Cell Interaction. (2016) (11)
Immune cell profiling in the cerebrospinal fluid of patients with primary angiitis of the central nervous system reflects the heterogeneity of the disease (2018) (11)
Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2 (2013) (11)
Classification of neurological diseases using multi-dimensional CSF analysis (2021) (11)
An autoreactive gamma delta TCR derived from a polymyositis lesion. (2002) (11)
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern (2009) (11)
Long-term efficacy of alemtuzumab in polymyositis (2014) (11)
Monomethylfumarate reduces in vitro migration of mononuclear cells (2014) (11)
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020 (2021) (11)
A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis (2015) (11)
Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies (2012) (11)
Multiple Sklerose – eine Kanalopathie? (2008) (11)
Modulation of neuronal activity by the endogenous pentapeptide QYNAD (2003) (10)
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis (2021) (10)
Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system (2020) (10)
B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non–PD-1–Mediated Pathway (2015) (10)
Cortex Parcellation Associated Whole White Matter Parcellation in Individual Subjects (2017) (10)
Infectious risk stratification in multiple sclerosis patients receiving immunotherapy (2017) (10)
Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke (2019) (10)
A fatal case of daclizumab-induced liver failure in a patient with MS (2019) (10)
K2P18.1 translates T cell receptor signals into thymic regulatory T cell development (2021) (10)
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment (2021) (10)
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. (2016) (10)
Fast track to becoming a regulatory T cell: “trogocytosis” of immune-tolerogenic HLA-G (2007) (9)
Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. (2010) (9)
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis (2017) (9)
Highlights from the 31st ECTRIMS congress – Barcelona 2015 (2016) (9)
Antigen recognition properties of a Vγ1.3Vδ2-T-cell receptor from a rare variant of polymyositis (2004) (9)
Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program (2020) (9)
Diagnostik der Multiplen Sklerose 2010 Revision der McDonald-Kriterien (2011) (9)
Correction: CD4+NKG2D+ T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation (2013) (9)
Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab (2011) (9)
VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells. (2019) (9)
Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses (2021) (9)
Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis (2021) (9)
Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134) (2012) (9)
Primary Angiitis of the CNS A Systematic Review and Meta-analysis (9)
Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP) (2016) (9)
Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals (2019) (9)
Acute transverse myelitis associated with coxiella burnetii infection (2002) (8)
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. (2017) (8)
Eculizumab versus rituximab in generalised myasthenia gravis (2022) (8)
Is APOE ε4 associated with cognitive performance in early MS? (2020) (8)
Intraocular dendritic cells characterize HLA-B27-associated acute anterior uveitis (2021) (8)
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis (2019) (8)
EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases (2019) (8)
Recent clinical trials and future therapies (2008) (8)
Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis (2021) (8)
Resolving the cognitive clinico-radiological paradox – Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis (2019) (8)
Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation. (2014) (8)
Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies (2020) (8)
Impact of T cells on neurodegeneration in anti‐GAD65 limbic encephalitis (2021) (7)
Evans syndrome associated with sterile inflammation of the central nervous system: a case report (2013) (7)
Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice. (2011) (7)
Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time (2815) (2020) (7)
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity (2022) (7)
Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses (2019) (7)
MCAM/CD146 Signaling via PLCγ1 Leads to Activation of β1-Integrins in Memory T-Cells Resulting in Increased Brain Infiltration (2020) (7)
Clinically relevant interaction of rivaroxaban and valproic acid – A case report (2020) (7)
Apraxia screening predicts Alzheimer pathology in frontotemporal dementia (2018) (7)
Multiple sclerosis therapy: An update on recently finished trials (2007) (7)
Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination (2019) (7)
No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3—antibodies (2006) (7)
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor) (2015) (7)
Rapidly progressive B-cell dominated inflammatory neuropathy and littoral cell angioma of the spleen associated with plasmablastic B-cell lymphoma (2012) (6)
Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis (2022) (6)
Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis (2018) (6)
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP) (2020) (6)
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) (2021) (6)
Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolytic–uremic syndrome (2015) (6)
Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry (2020) (6)
TERI-DYNAMIC: Exploring the Impact of Teriflunomide on Immune Cell Population Size, Receptor Repertoire, and Function in Patients With RRMS (P5.282) (2016) (6)
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients (2016) (6)
Safety and Tolerability Results From the DECIDE Study: A Phase 3 Active-Comparator Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis (P7.230) (2015) (6)
Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease (2022) (6)
Very bright dorsal columns: spinal magnetic resonance imaging in funicular myelosis. (2002) (6)
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets (2021) (6)
Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie (2016) (6)
A b-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis (2008) (6)
Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003) (2015) (6)
Neuroinflammation: the world is not enough. (2012) (6)
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial (2021) (6)
Neonatal Fc Receptor–Targeted Therapies in Neurology (2022) (6)
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]. (2021) (6)
CD3-Positive B Cells: A Storage-Dependent Phenomenon (2014) (6)
Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis (2022) (5)
Expression and role of novel B7 family members in human muscle: implications for the pathogenesis of inflammatory myopathies (2004) (5)
Defining mechanisms of neural plasticity after brainstem ischemia in rats (2018) (5)
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis (2022) (5)
The STING-IFN-β-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis (2020) (5)
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP) (2021) (5)
Trafficking of lymphocytes into the CNS (2015) (5)
Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis (2019) (5)
Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas (2022) (5)
Association of obesity with disease outcome in multiple sclerosis (2022) (5)
Clinical Course, Myopathology and Challenge of Therapeutic Intervention in Pediatric Patients with Autoimmune-Mediated Necrotizing Myopathy (2021) (5)
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data (2021) (5)
Postpartum disease activity and breastfeeding in multiple sclerosis revisited (2010) (5)
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us? (2022) (5)
A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation (2018) (5)
Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms (2015) (5)
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE (2017) (5)
Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy (2021) (5)
Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia (2018) (5)
ECTRIMS-EAN clinical practice guideline on pharmacological management of multiple sclerosis. (2016) (5)
Human herpesvirus 6 in serum and spinal fluid of patients with multiple sclerosis? (2003) (5)
Genetic determinants of the humoral immune response in MS (2020) (5)
Cholesterinsenker—eine neue Therapieoption bei Multipler Sklerose? (2003) (5)
High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses (2022) (5)
NMO Spectrum Disorders (2017) (5)
Teriflunomid zur Behandlung der Multiplen Sklerose (2013) (5)
Nuclear Receptor Control of Myeloid Cell Responses - Implications for CNS Autoimmunity (2013) (5)
Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. (2021) (5)
Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen (2007) (5)
Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose (2015) (5)
Impaired Autonomic Responses to Emotional Stimuli in Autoimmune Limbic Encephalitis (2015) (5)
Hyponatremia upon presentation to the emergency department – the need for urgent neuroimaging studies (2017) (5)
Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system (2015) (5)
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice (2021) (5)
Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab (2017) (4)
Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose (2021) (4)
New evidence for teriflunomide in multiple sclerosis (2014) (4)
Structured Delirium Management in the Hospital-a Randomized Controlled Trial. (2022) (4)
Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (2019) (4)
Treosulfan impedes the migration of immunocompetent cells (2007) (4)
Correction: A β-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis (2008) (4)
Defining the architecture of cerebrospinal fluid cellular communities in neuroinflammatory diseases (2021) (4)
Expression of Molecules Involved in Fetal-Maternal Tolerance Allows Human Mesenchymal Stem Cells to Engraft at High Levels across Immunologic Barriers (2008) (4)
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS (2019) (4)
Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time (2019) (4)
Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose (2021) (4)
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier. (2017) (4)
Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients (2019) (4)
Konzepte zur Läsionsentstehung bei Multipler Sklerose (2006) (4)
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. (2011) (4)
Determinants of cognition in autoimmune limbic encephalitis—A retrospective cohort study (2021) (4)
Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis (2017) (4)
Auto-SCT in severe paraproteinemic neuropathy (2011) (4)
An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function (2017) (4)
[Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature]. (2005) (4)
Progressive multifokale Leukenzephalopathie unter Natalizumab (2011) (4)
Transcriptional Repressor HIC 1 Contributes to Suppressive Function of Human Induced Regulatory T Cells (2018) (4)
The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome (2021) (4)
[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]. (2019) (4)
DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis (2018) (4)
Demenz als Erstsymptom bei spät beginnender Multipler Sklerose (2004) (4)
INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS (2009) (4)
Profiling Complement System Components in Primary CNS Vasculitis (2021) (4)
Multiple Sklerose Aktuelle Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien (2000) (4)
Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement? (2021) (4)
A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis (2022) (4)
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses (2022) (4)
Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity (2021) (4)
Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments (2021) (4)
Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases (2021) (4)
Comment on "Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse". (2009) (3)
NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection (2021) (3)
Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals (2020) (3)
Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report (2022) (3)
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021 (2022) (3)
Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions (2021) (3)
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis (2022) (3)
Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions (2020) (3)
An enigmatic case of cortical anopsia: Antemortem diagnosis of a 14-3-3 negative Heidenhain-variant MM1-sCJD (2019) (3)
Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma (2022) (3)
Sodium chloride-high diet promotes pro-inflammatory macrophage activation and aggravates central nervous system autoimmunity (2014) (3)
Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging (2018) (3)
Comparison of Patients Treated with Natalizumab and Interferon-beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data (P01.211) (2013) (3)
The neuroinflammation biobank in the Department of Neurology, University Hospital Muenster, Germany. (2014) (3)
[Blocking adhesion molecules with natalizumab in multiple sclerosis]. (2005) (3)
Genetic variants associated with intrathecal synthesis of IgG, IgM and IgA in multiple sclerosis (2016) (3)
[Current aspects of therapy conversion for multiple sclerosis]. (2015) (3)
Multiple sclerosis: advances, excitements, disenchantments (2006) (3)
Transforming multiple sclerosis trials into practical reality (2011) (3)
Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer (2018) (3)
An ex vivo model of an oligodendrocyte-directed T-cell attack in acute brain slices. (2015) (3)
Review and Analysis of International Case-Control Studies on CCSVI and Multiple Sclerosis (2013) (3)
Complement activation contributes to GAD antibody-associated encephalitis (2022) (3)
Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions (2021) (3)
UVB light attenuates the systemic immune response in CNS autoimmunity (2014) (3)
Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis (2020) (3)
Daclizumab HYP versus Interferon β-1a across Patient Demographic and Disease Activity Subgroups in the DECIDE Phase 3 Study (P4.007) (2015) (3)
Muscle ® bres and cultured muscle cells express the B 7 . 1 / 2-related inducible co-stimulatory molecule , ICOSL : implications for the pathogenesis of in ̄ ammatory myopathies (2003) (3)
Therapeutische monoklonale Antikörper in der Neurologie (2010) (3)
Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype (2021) (3)
Detecting myasthenia gravis as a cause of unclear dysphagia with an endoscopic tensilon test (2021) (3)
Serial position effects rapidly distinguish Alzheimer’s from frontotemporal dementia (2019) (3)
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis (2022) (3)
Cells : A Potential Mechanism of Immune Paralysis Expression of the B 7-Related Molecule B 7-H 1 by Glioma Updated (2003) (3)
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings (2011) (3)
Dysphagia in NMOSD and MOGAD as a surrogate of brain involvement? (2020) (3)
An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis (2018) (2)
Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) (2020) (2)
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets (2022) (2)
Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study. (2021) (2)
CT Hypoperfusion-Hypodensity Mismatch to Identify Patients With Acute Ischemic Stroke Within 4.5 Hours of Symptom Onset (2021) (2)
Real-World Safety and Efficacy of Natalizumab after Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) (P2.069) (2016) (2)
Towards a dendritic cell-based vaccine for the treatment of multiple sclerosis (MS): interim safety data of the first dose cohort of the MS-tolDC phase I clinical trial (2018) (2)
Multiple Sclerosis Update (2011) (2)
In treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS), initiating natalizumab earlier is associated with greater disability improvement than delaying treatment: real-world results from the TYSABRI® Observational Program (TOP) (P6.350) (2017) (2)
Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results) (2020) (2)
Deterministic programming of human pluripotent stem cells into microglia facilitates studying their role in health and disease (2022) (2)
Long-Term Sonographical Follow-Up of Arterial Stenosis Due to Spontaneous Cervical Artery Dissection (2022) (2)
High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients (2020) (2)
Myalgia with the presence of pathologic EMG correlates with perimysial inflammatory infiltrates (2019) (2)
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment (P3.054) (2016) (2)
Single-cell transcriptomics identifies drivers of local inflammation in multiple sclerosis (2018) (2)
Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients (2022) (2)
Comparison of Switching to Natalizumab Versus Remaining on Interferon-Beta or Glatiramer Acetate after On-Treatment MS Relapse Using Propensity-Matched Registry Data (P7.208) (2014) (2)
Simplified Assessment of Lesion Water Uptake for Identification of Patients within 4.5 Hours of Stroke Onset: An Analysis of the MissPerfeCT Study (2022) (2)
Blockade von Adhäsionsmolekülen mit Natalizumab in der Therapie der Multiplen Sklerose (2005) (2)
[Therapeutic monoclonal antibodies in clinical neurology]. (2010) (2)
Correction: A β-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis (2011) (2)
A novel NMDA receptor test model based on hiPSC-derived neural cells (2023) (2)
The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis (2020) (2)
Multiple Sklerose und andere demyelinisierende Erkrankungen (2012) (2)
Dose-dependent melanonychia by mitoxantrone (2009) (2)
Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis (2013) (2)
Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature (2020) (2)
The metalloproteinase‐disintegrin ADAM10 is exclusively expressed by type I muscle fibers (2008) (2)
[Progressive multifocal leukoencephalopathy and rheumatic disease]. (2008) (2)
Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252) (2015) (2)
JCV index and L-selectin for natalizumab-associated PML risk stratification (2014) (2)
Aktuelles zur Therapieumstellung bei Multipler Sklerose (2015) (2)
Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM (2013) (2)
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta (2018) (2)
Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis (2021) (2)
Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI(R) observational programme (2012) (2)
[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ]. (2006) (2)
Impact of complement activation on clinical outcomes in multiple sclerosis (2021) (2)
Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort (2022) (2)
Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke (2022) (2)
Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease (2021) (2)
Stroke induces disease-specific myeloid cells in the brain parenchyma and pia (2022) (1)
Case report of bilateral relapsing-remitting sciatic nerve palsy during two pregnancies (2015) (1)
Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndrom (2012) (1)
The pathophysiological role of cytotoxic CD8 T cells in Susac syndrome (2014) (1)
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (2022) (1)
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. (2023) (1)
Occurrence of status epilepticus in persons with epilepsy is determined by sex, epilepsy classification, and etiology: a single center cohort study (2021) (1)
Observational Program Tysabri 24 Plus: Evaluating Efficacy and Safety of Natalizumab Therapy beyond Two Years (P01.161) (2013) (1)
CD4+ CD25+ FoxP3+ regulatory T cells suppress cytotoxicity of CD8+ effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level (2012) (1)
Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction – A systematic review and meta-analysis (2023) (1)
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study (2023) (1)
Humoral signatures of MOG-antibody-associated disease track with age and disease activity (2023) (1)
[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]. (2007) (1)
Delayed onset and reduced disease severity of spontaneous CNS autoimmunity by conjugated linoleic acid-rich diet (P2.217) (2015) (1)
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide (2022) (1)
Response to letter regarding article, "blocking of α4 integrin does not protect from acute ischemic stroke in mice". (2014) (1)
Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis (2010) (1)
Diagnostik und Therapie von Tuberkulose unter Immuntherapien für Multiple Sklerose (2019) (1)
Patients with a relapsing course of steroid‐responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T‐cell activation (2020) (1)
Comparative Efficacy of Switching to Natalizumab Versus Switching to Interferon-Beta or Glatiramer Acetate after On-Treatment MS Relapse Using Propensity-Matched Registry Data (P3.175) (2014) (1)
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies (2022) (1)
[Concentric Sclerosis Baló: A rare Variant of Multiple Sclerosis]. (2013) (1)
CNS Pericytes Modulate Local T Cell Infiltration in EAE (2022) (1)
Sicherheitsmaßnamen und Abwägung der Risiken in der RRMS-Therapie (2016) (1)
Übersicht und Analyse internationaler Fall-Kontroll-Studien zu „Chronischen zerebrospinalen venösen Insuffizienz“ (CCSVI) und Multipler Sklerose (2013) (1)
Cytokine-Based Therapeutics for Intrinsic CNS Disease Processes (2005) (1)
4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – No (2020) (1)
Multiple Sklerose – Revision der neuen McDonald-Diagnosekriterien (2006) (1)
MAPT genotype-dependent mitochondrial aberration and ROS production trigger dysfunction and death in cortical neurons of patients with hereditary FTLD (2022) (1)
Immunotherapy of multiple sclerosis (2009) (1)
Patients with a relapsing course of SREAT exhibit persistent intrathecal CD4+ T cell activation. (2020) (1)
Expression of HLA-G1 and G5 Enables Human Mesenchymal Stem Cells To Engraft at High Levels across Xenogeneic Barriers Following Transplantation into Immunocompetent Recipients. (2007) (1)
Neuromyelitis-optica-Spektrum-Erkrankungen – alte und neue Entwicklungen (2020) (1)
Pegyliertes Interferon-beta 1a (2015) (1)
A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis (2022) (1)
Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy (2020) (1)
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]. (2011) (1)
Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis (2014) (1)
Why a positive genetic test for myotonic dystrophy type I does not always imply the right diagnosis (2006) (1)
The bile acid receptor FXR controls CNS autoimmunity in an IL-10-dependent fashion (2014) (1)
Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 (P5.349) (2017) (1)
Intra-ocular dendritic cells are increased in HLA-B27 associated acute anterior uveitis (2021) (1)
Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters (2022) (1)
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study (P3.059) (2016) (1)
B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356) (2020) (1)
Immune Cell Profiling during Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of non-T Cell Populations into the CSF – Results from the ToFingo Successor Study (S52.002) (2018) (1)
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets (2022) (1)
Single cell PCR analysis of the intrathecal plasma cell repertoire in autoimmune encephalitis (P4.063) (2015) (1)
Antigen recognition properties of a Vgamma1.3Vdelta2-T-cell receptor from a rare variant of polymyositis. (2004) (1)
Antibody response to herpes simplex virus‐1 is increased in autoimmune encephalitis (2022) (1)
Behandlung der multiplen Sklerose (2003) (1)
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound (2022) (1)
[Multiple sclerosis: potential therapeutic options and update of ongoing studies]. (2004) (1)
Real-world improvement across functional systems (FS) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab in the TYSABRI® Observational Program (TOP) (P6.383) (2018) (1)
mice by inducing dysfunction of the cerebral microvasculature Regulatory T cells are strong promoters of acute ischemic stroke in (2013) (1)
Influence of ultraviolet radiation and diminished-function melanocortin 1 receptor variants on multiple sclerosis disease severity in two large multicenter cohort studies (2019) (1)
[Teriflunomide for treatment of multiple sclerosis]. (2013) (1)
Dietary Conjugated Linoleic Acid Supplementation Modulates CNS Autoimmunity (P2.413) (2018) (1)
Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies (2012) (1)
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results) (2019) (1)
THUR 174 The magnify-ms study: mavenclad® tablets in active rms (2018) (1)
NMO-Spektrum-Erkrankungen (2016) (1)
Identification of Autoantibody Producing Plasma Cells in the CSF of Autoimmune Encephalitis (AIE) Patients (P6.132) (2016) (1)
Immunpathogenese und Therapie inflammatorischer Myopathien (2008) (1)
A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies (2022) (1)
Multiple Sklerose: potenzielle Therapieansätze und Update laufender Studien (2004) (1)
Ionenkanalmodulatoren bei Multipler Sklerose (2011) (1)
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies (2021) (1)
Alemtuzumab efficacy and safety were durable over 5 years after switching from SC IFNB-1a : follow-up of patients from CARE-MS II (TOPAZ study) (2017) (1)
Alemtuzumab bei schubförmig-remittierender multipler Sklerose (2013) (1)
Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy (2020) (1)
Potassium channel modulation - a therapeutic principle? 4-Aminopyridine in autoimmune central nervous system disease (2011) (0)
Affinity-dependent effects of Teriflunomide and impact on T cell metabolism (2014) (0)
Neuropsychological impairment in newly diagnosed early multiple sclerosis: clinical and neuropsychological characterization of a German cohort of 1124 patients (2017) (0)
Two-pore domain potassium channels are novel targets for autoimmune myopathies by influencing basic cellular parameters in murine muscle cells (2014) (0)
First results of a prospective cohort study in clinically isolated syndromes and early multiple sclerosis of the German Competence Network Multiple Sclerosis (2015) (0)
Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016) (2023) (0)
Identification of functionally relevant genetic variants associated with multiple sclerosis using deep learning (2019) (0)
Primary Angiitis of the CNS (2021) (0)
Properties and molecular characteristic of immune regulation of human thymus-derived CD4+HL−G+ regulatory T cells in vitro and in vivo (2014) (0)
Stroke in patients with bacterial meningitis: A cohort study and meta-analysis. (2023) (0)
Rabies virus has more than one trick up its sleeve to manipulate the host defences (2008) (0)
[Neuromyelitis Optica Spectrum Disorders - Present Insights and Recent Developments]. (2021) (0)
Factor XII drives CNS autoimmunity via CD87-mediated modulation of dendritic cells (2014) (0)
Implications of the PD-1/B7-H1 receptor-ligand system in Alzheimer's Disease (2008) (0)
Natalizumab long-term therapy for relapsing MS in clinical routine: Final results of the prospective observational multicenter study Tysabri® 24 plus (2013) (0)
The impact of immune cells on genetically-caused myelin injury in the CNS (2007) (0)
Evoked potential abnormalities in RRMS patients are improved under natalizumab therapy (2011) (0)
199 Changes in natalizumab exposure and PML incidence over time (2019) (0)
Nervous System Inflammation Activation in Murine Autoimmune Central Key Regulators of Autoreactive T Cell Stromal Interaction Molecules 1 and 2 Are (2010) (0)
Baseline Results of the Prospective Nationwide Cohort Study in Clinically Isolated Syndromes and Early Multiple Sclerosis of the German Competence Network Multiple Sclerosis and Monocentric Subgroup Analysis of Neuropsychological Findings (P1.392) (2016) (0)
Assessment of Baseline Characteristics, Treatment Efficacy, and Serious Adverse Events among Natalizumab-Treated MS Patients without Prior Treatment (P06.172) (2012) (0)
Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment (2016) (0)
New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits (2017) (0)
Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3 (2018) (0)
Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry (2023) (0)
No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis (2019) (0)
Safety and feasibility of a tolerogenic dendritic cell-based treatment of multiple sclerosis (MS): a collaborative initiative comparing intranodal and intradermal cell administration in two phase I clinical trials (2018) (0)
Autoimmunity via a Novel Non Differentiation and Central Nervous System 17 HB 7-H 1 Selectively Controls T (2015) (0)
The NKG2D signaling pathway is a possible therapeutic target for autoimmune myositis (2014) (0)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2020) (0)
Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus (2018) (0)
B7-homologue 1 inhibits T cell-mediated blood–brain barrier disruption and regional encephalitogenicity in a spontaneous model of CNS autoimmunity (2014) (0)
Case report of bilateral relapsing-remitting sciatic nerve palsy during two pregnancies (2015) (0)
B7-H1 (PD-L1) modulates neuroantigen-specific T-cell expansion and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis (2007) (0)
Erratum: Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (Cell (2019) 178(1) (262), (S0092867419306798), (10.1016/j.cell.2019.06.016)) (2020) (0)
Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis (2019) (0)
Prospective, multicentric study of using JCV serology and L-selectin for PML risk assessment (2016) (0)
The nuclear receptor Nur77 restricts T cell responses and limits central nervous system autoimmunity (2014) (0)
Use of blockers of the NKG2D receptor / NKG2D ligand interaction in autoimmune diseases (2004) (0)
Neonatal Fc Receptor–Targeted Therapies in Neurology (2022) (0)
NOX4-derived ROS are neuroprotective by balancing intracellular calcium stores (2023) (0)
Schwann cells as conditional antigen presenting cells in inflammatory neuropathies (2007) (0)
Optimized synthesis and pharmacological evaluation of HCN channel inhibitor EC18. (2023) (0)
The Role of Leukemia Derived B7-H1 in Tumor-T-Cell Interactions in Humans. (2005) (0)
C URRENT OPINION Immune mechanisms of stroke (2012) (0)
Case Report: A Spinal Ischemic Lesion in a 24-Year-Old Patient With Fabry Disease (2020) (0)
Review and meta-analysis of neuropsychological findings in autoimmune limbic encephalitis with autoantibodies against LGI1, CASPR2, and GAD65 and their response to immunotherapy (2022) (0)
Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis (2022) (0)
Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity after the Initial Two Courses: Results from the CARE-MS II Extension (2018) (0)
Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015) (2023) (0)
Transition to non-active secondary progressive multiple sclerosis (SPMS) after up to 9.5 years of natalizumab treatment in the real-world TYSABRI Observational Program (TOP) (2802) (2020) (0)
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. (2022) (0)
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. (2022) (0)
085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri® observational program (TOP) (2018) (0)
Impaired Immune Regulatory Function of Natural Killer (NK) Cells in Multiple Sclerosis (MS) (P1.173) (2014) (0)
A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies (2022) (0)
POLG mutations had a mixed axonal-demyelinating type of sensory neuropathy. Discussion. External ophthalmoplegia and (in par- ticular axonal) sensory neuropathy are highly sugges- tive of underlying POLG mutations in patients with cerebellar ataxia in which common SCA and FRDA (2009) (0)
Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis (2020) (0)
Assessment of clinical disease activity and disability improvement by number-needed-to-treat analyses in patients with relapsing multiple sclerosis treated with alemtuzumab or ocrelizumab (2018) (0)
IMMUNOLOGICAL AND INFLAMMATORY DISORDERS OF THE CENTRAL NERVOUS SYSTEM. (1999) (0)
Efficacy, Safety and JC-Antibody Prevalence Following Natalizumab Treatment for 36 Month and More in Patients with Relapsing Remitting Multiple Sclerosis (P02.135) (2012) (0)
NKG2D - IL-15 Signaling Is Critically Involved in the Pathogenesis of Inflammatory Myopathies (I4.002) (2016) (0)
Bruton tyrosine kinase inhibitors for multiple sclerosis (2023) (0)
ORAL PRESENTATIONS (2003) (0)
Immunophenotyping of cerebrospinal fluid cells by Chipcytometry (2018) (0)
Absence of Epstein-Barr virus seronegativity in a large cohort of patients with early multiple sclerosis (2018) (0)
Correction: PD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation (2011) (0)
Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16.006) (2023) (0)
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients (2022) (0)
Longer duration of natalizumab exposure may lessen return of disease activity following a switch from natalizumab to an oral therapy: modelling real-world data from relapsing-remitting multiple sclerosis (RRMS) patients in the TYSABRI® Observational Program (TOP) (P6.379) (2018) (0)
Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis (2016) (0)
Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells (2010) (0)
Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis. (2023) (0)
212 DEFICIENCY OF THE NEGATIVE IMMUNE REGULATOR B7H1 ENHANCES INFLAMMATION AND NEUROPATHIC PAIN AFTER CHRONIC CONSTRICTION INJURY OF MOUSE SCIATIC NERVE (2010) (0)
Targeting MCAM for next-generation modulation of leucocyte trafficking. (2023) (0)
Correction: Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis (2022) (0)
Novel pathomechanisms in inflammatory neuropathies (2017) (0)
Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis (2022) (0)
Number Needed to Treat Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab or Ocrelizumab (P6.384) (2017) (0)
K2P18.1 translates T cell receptor signals into thymic regulatory T cell development (2021) (0)
Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension (P6.363) (2018) (0)
Changes of disease characteristics and disease-modifying treatment within one year in the National German MS cohort (2018) (0)
Functional Expression of K2P Potassium Channels in Tumor Infiltrating Lymphocytes of Malignant Glioma (P7.012) (2014) (0)
OBSERVATION CD 4 T Cells Predominate in Cerebrospinal Fluid and Leptomeningeal and Parenchymal Infiltrates in Cerebral Amyloid – Related Angiitis (2012) (0)
Was gibt es Neues bei der Multiplen Sklerose? (2012) (0)
ALEMTUZUMAB IMPROVES EDSS FUNCTIONAL SYSTEMS SCORES IN RRMS (2016) (0)
Alemtuzumab improves disability and quality of life outcomes over 8 years in patients with RRMS (2019) (0)
P 42. ALS patients show increased T-cell activation in peripheral blood and cerebrospinal fluid (2021) (0)
Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment (2012) (0)
The nuclear receptor NR4A1 restrains neutrophil granulocyte mediated brain damage in cerebral ischemia (2022) (0)
Pathogenese und Diagnostik der Rasmussen-Enzephalitis (2008) (0)
Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change (S16.009) (2023) (0)
Reply to “Investigating the Immunopathogenic Mechanisms Underlying MOGAD” (2021) (0)
P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin (2019) (0)
Intrathecal immunoglobulin synthesis as a predictive marker for disability progression in multiple sclerosis (2017) (0)
Blockade of MCAM on T(H)17 cells impedes their CNS infiltration over the choroid plexus (2017) (0)
Therapy with Natalizumab Is Associated with High JCV Sero-Conversion and Rising JCV Index Values (P2.064) (2016) (0)
MMF induces antioxidative and anaplerotic pathways and is neuroprotective in hyperexcitability in vitro. (2022) (0)
Immune Escape Human Gliomas: An Alternative Strategy of A Functional Role of HLA-G Expression in (2013) (0)
[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis]. (2015) (0)
Impaired B Cell Expression of the Inhibitory Fcγ Receptor IIB in Myasthenia Gravis (2022) (0)
Lysosomes from Human B Lymphocytes the Processing of Myelin Basic Protein in Asparagine-Specific Endoprotease , Controls Cathepsin G , and Not the (2004) (0)
Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer (2016) (0)
Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096) (2019) (0)
Letter to the editor regarding "Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials". (2023) (0)
Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study (2023) (0)
Acetylcholine receptor specific T-cell responses in myasthenia gravis Prominent response of the epsilon-subunit (2002) (0)
[Frequency and risk factors associated with post-stroke dementia-an observational study on stroke patients without premorbid cognitive impairment]. (2019) (0)
Complement activation profiles in anti‐acetylcholine receptor positive myasthenia gravis (2023) (0)
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab (2023) (0)
Novel Multiple Sclerosis Genetic Risk Factors Are Involved in Epigenetic Regulation (S37.006) (2016) (0)
blocking of Trpm2 channels protects from ischemic neurodegeneration in mice by reducing oxidative stress, blood-brain-barrier damage and inflammation : Ep3212 (2014) (0)
Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation? (2017) (0)
Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment (2016) (0)
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. (2022) (0)
Pregabalin and gabapentin treatment in MS patients: Clinical experiences and therapeutic implications (2011) (0)
Exome Array GWAS in 10,000 Germans Identifies Association between MUC22 and Multiple Sclerosis (2015) (0)
DGN-(German Society for Neurology)-Congress 2012-5000 Neurologists explore new Ways for the Prevention and Therapy of Brain Diseases (2012) (0)
Regulation of lymphocyte adhesion and migration into the CNS by phospholipase D1 in autoimmune neuroinflammation (2014) (0)
P 24. Dysphagia in NMOSD and MOGAD: Swallowing endoscopy as a surrogate of brain involvement? (2021) (0)
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy (2023) (0)
A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2 (2018) (0)
Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum (2023) (0)
Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-5.014) (2023) (0)
[Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators]. (2003) (0)
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses (2022) (0)
[Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies]. (2013) (0)
Identification of multiple sclerosis endophenotypes by high dimensional blood signatures associated with distinct disease trajectories (P1-3.008) (2023) (0)
Hyponatremia upon presentation to the emergency department – the need for urgent neuroimaging studies (2017) (0)
[Prognostic and predictively relevant factors for multiple sclerosis]. (2014) (0)
Autoimmune encephalitis: Single cell PCR analysis of the intrathecal plasma cell repertoire (2014) (0)
Failed reproduction attempt by Biogen due to changed protocols, method of analysis, and poor biomaterial quality (2020) (0)
Abstract 458: Immune-inhibitory HLA-G is expressed in the tumor microenvironment of Ewing Sarcomas (2015) (0)
Comparative case series of GABA(B) and AMPA receptor antibodies associated with limbic encephalitis (2014) (0)
P.027 Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses (2018) (0)
Pathogenicity of Rasmussen Encephalitis CD8+ Lymphocytes Elucidated by Large-Scale Sequencing of the T-Cell Receptor Repertoire (P5.242) (2016) (0)
[Not Available]. (2015) (0)
Cross-sectional and longitudinal analysis of clinical parameters in a large-scale, national, multicentric multiple sclerosis cohort and the influence of MC1R SNPs (2018) (0)
Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis (2015) (0)
Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration (2019) (0)
O 6: Kininogen Deficiency Ameliorates Neuroinflammation by Reducing Immune Cell Trafficking (2017) (0)
023 Relapse outcomes with natalizumab Q4W vs switch to Q6W (2022) (0)
Review of Novel Immunotherapeutic Strategies for MS (2007) (0)
Real-World Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the Tysabri® Observational Program (TOP) Who Discontinued Natalizumab: Why They Stopped, Which Therapies They Switched To, and How Their Disease Activity Changed (P2.399) (2017) (0)
Frankfurter Allgemeine Zeitung Verlagsspezial (2019) (0)
PO152 Alemtuzumab efficacy in patients with relapse after course 1 (2017) (0)
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”) (2015) (0)
Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis (2023) (0)
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis (2022) (0)
Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC (2015) (0)
Immunological Signatures Associated With Ocrelizumab Treatment in Early RRMS: 12-Month Interim Analysis From the Ocrelizumab Phase IIIb (ENSEMBLE; NCT03085810) Immunological Substudy (S16.003) (2023) (0)
the Dysfunctional Immune Regulation in Plasmacytoid Dendritic Cells Characterizes Phenotypically Different Subsets of An Imbalance of Two Functionally and (2017) (0)
Author response: Defective synaptic transmission causes disease signs in a mouse model of juvenile neuronal ceroid lipofuscinosis (2017) (0)
Relationship between baseline treatment history and post baseline relapses and serious adverse events in natalizumab-treated patients with multiple sclerosis (2011) (0)
Gut-CNS axis as mediator of protective effect of conjugated linoleic acid on CNS autoimmunity (2019) (0)
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort (2023) (0)
Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses (2017) (0)
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. (2023) (0)
Correction: Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9) (2013) (0)
Endothelial TREK1 Potassium Channels Are Critical Regulators of Immune Cell Migration Into the CNS (S14.001) (2014) (0)
COVID-19 ASSOCIATED RISKS AND EFFECTS IN MYASTHENIA GRAVIS (CARE-MG): AN INTERNATIONAL PHYSICIAN-REPORTED REGISTRY (2020) (0)
Prospective multicenter validation of CSF protein biomarkers in patients with CIS and early MS (2018) (0)
Bilaterality of temporal EEG findings in limbic encephalitis compared to other mesiotemporal epilepsies – A retrospective cohort study (2022) (0)
Results of cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy (2020) (0)
Amygdala enlargement and emotional responses in (autoimmune) temporal lobe epilepsy (2018) (0)
A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates (2019) (0)
Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone (2021) (0)
Re:Time to audit all reported PML cases (2019) (0)
Longer-term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis (2021) (0)
Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination (2018) (0)
Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017) (2023) (0)
Dietary supplementation with conjugated linoleic acid influences central nervous system autoimmunity via the gut-central nervous system axis (2018) (0)
Altered grey matter networks in young patients with MS at genetic risk for Alzheimer's disease (2017) (0)
Long-Term Course and Clinical Assessment Parameters of Patients With Multiple Sclerosis Under Dalfampridine (P7.248) (2014) (0)
Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) (2019) (0)
High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies (2022) (0)
Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age (P6-3.016) (2023) (0)
O 3:Therapeutic Potential of a Novel NMDA Receptor Subunit 2B Antagonist in a Mouse Model of Autoimmune Neuroinflammation (2017) (0)
Author response: Intraocular dendritic cells characterize HLA-B27-associated acute anterior uveitis (2021) (0)
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis (P8-3.004) (2023) (0)
FP33-WE-01 TYSABRI® observational program: a long-term evaluation of safety and impact on disease activity and progression of natalizumab in relapsing-remitting MS (2009) (0)
No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (2018) (0)
O6.04GRANULOCYTIC MYELOID-DERIVED CELLS OBTAINED FROM BLOOD MAINLY SUPPRESS T-CELL PROLIFERATION IN PATIENTS WITH GLIOBLASTOMA (2014) (0)
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis (2023) (0)
Detecting myositis as a cause of unexplained dysphagia: Proposal for a diagnostic algorithm (2021) (0)
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications (2015) (0)
Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis (2020) (0)
T lymphocytes correlates with disease activity in rheumatoid arthritis patients (2011) (0)
Dimethyl Fumarate Treatment alters T Cell Metabolism in Multiple Sclerosis (P1.414) (2018) (0)
Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558) (2020) (0)
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID) (2015) (0)
Association of age with 1-year outcome in patients with acute ischaemic stroke treated with thrombectomy: real-world analysis in 18 506 patients (2023) (0)
Vorstellung des neugegründeten krankheitsbezogenen Kompetenznetz Multiple Sklerose (2009) (0)
OP0056 12/15-lipoxygenase mediates GC-induced anti-inflammatory mechanisms in monocytes (2013) (0)
Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies (2022) (0)
Monocyte-derived HLA-G, a strong inhibitor of autologous CD4 T-cell activation, is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis? (2004) (0)
Was gibt es Neues bei der Multiplen Sklerose? (2011) (0)
SFB-TR 128: Multiple Sklerose: Von einem neuen Verständnis der Pathogenese zur Therapie (2013) (0)
Dimethylfumarat in der Therapie der schubförmigen MS (2014) (0)
Unklare neurologische Symptomatik bei extraduralem spinalem Meningeom im Bereich des zervikothorakalen Überganges (1998) (0)
Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter (2013) (0)
Therapie der Rasmussen-Enzephalitis* (2008) (0)
Der monoklonale Antikörper Eculizumab reduziert bei NMOSD die Schubraten (2019) (0)
Sicherheit durch Behandlungsempfehlungen und Therapieregister (2014) (0)
Neuromyelitis-optica-Spektrum-Erkrankungen – alte und neue Entwicklungen (2021) (0)
Verbesserung und Update der PML-Risikoberechnung (2017) (0)
Orales Fingolimod (FTYP720) versus Placebo bei primär progredienter Multipler Sklerose: Studiendesign einer Phase III-Studie (2009) (0)
Patients with RRMS Who Had an Inadequate Response to a Prior Therapy Demonstrated Durable Improvement in EDSS Functional Systems Scores Over 5 Years with Alemtuzumab (P6.186) (2016) (0)
Selektive IgG-Reduktion verringert Symptome (2021) (0)
Chancen und Risiken des Einsatzes von Biosimilars und Non-Biological Complex Drugs in der Multiple Sklerose Therapie (2017) (0)
Vielversprechender Therapieansatz (2021) (0)
Aktuelles zur MS-Therapie: Orale Therapeutika (2010) (0)
Häufigkeit und Risikofaktoren der Post-Stroke-Demenz – eine Beobachtungsstudie zu Schlaganfallpatienten ohne vorbestehende kognitive Defizite (2019) (0)
FTY720– eine neue orale, einmal täglich anzuwendende therapeutische Option für Multiple Sklerose: Update aus dem internationalen Studienprogramm (2008) (0)
Does an artistic representation of brand logos increase their effect on customers? (2021) (0)
Bedeutung nichtklassischer MHC-Moleküle in der Immunpathogenese der MS (2010) (0)
MS-Versorgung heute und Vision für die Zukunft - eine Rolle für die ASV? (2022) (0)
Chronische Enzephalitis mit Epilepsie (Rasmussen-Enzephalitis) - Infektion, Autoimmunkrankheit oder Epiphänomen? (2000) (0)
Erratum zu: Neuromyelitis-optica-Spektrum-Erkrankungen – alte und neue Entwicklungen (2020) (0)
Antikörpernegative limbische Enzephalitis mit Beteiligung von Dienzephalon und Hirnstamm (2012) (0)
Neuromyelitis-optica-Spektrum-Erkrankungen – alte und neue Entwicklungen (2020) (0)
Die Zukunft liegt im Netzwerk (2015) (0)
Correction (2019) (0)
Leitlinie Dermatomyositis – Auszug aus der interdisziplinären S2k‐Leitlinie zu Myositissyndromen der deutschen Gesellschaft für Neurologie (2016) (0)
Multiple Sklerose: Der Beginn einer neuen Ära (2015) (0)
Beobachtungsstudie zur Sicherheit und Verträglichkeit von Betaferon nach vorangegangener Mitoxantrontherapie (AMBOSS – After Mitoxantrone Betaferon – Observational Safety Study) (2008) (0)
Rasch progrediente demenzielle Entwicklung als initiales Symptom einer Neuromyelitis optica (NMO) (2014) (0)
Immuntherapie heute (2012) (0)
Tysabri® Observational Program: Langzeit-Analyse der Arzneimittel-Sicherheit sowie von Krankheits-Aktivität und Behinderungs-Progression bei mit Tysabri® (Natalizumab) behandelten Patienten mit schubförmig-remittierender Multibler Sklerose (2009) (0)
Myasthenia gravis und myasthene Syndrome (2012) (0)
Therapie der Multiplen Sklerose (2016) (0)
Bilanz erster Förderperiode und Ausblick auf zukünftige Projekte (2012) (0)
Myositiden: Pathogenese und Therapie (2015) (0)
Neurologie (2007) (0)
Perspektiven der klinischen Multiple-Sklerose-Forschung und -Therapie (2001) (0)
Prognostische und prädiktiv relevante Faktoren bei der Multiplen Sklerose (2014) (0)
054 Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension (2018) (0)
Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials (2019) (0)

This paper list is powered by the following services:

Other Resources About Heinz Wiendl

en.wikipedia.org

What Schools Are Affiliated With Heinz Wiendl?

Heinz Wiendl is affiliated with the following schools:

Heinz Wiendl's Academic­Influence.com Rankings

Heinz Wiendl's Degrees

Why Is Heinz Wiendl Influential?

Heinz Wiendl's Published Works

Published Works

Other Resources About Heinz Wiendl

What Schools Are Affiliated With Heinz Wiendl?

Heinz Wiendl's AcademicInfluence.com Rankings